SCHEMBL2869212

SCHEMBL2869212

CN1CCN(CCCNc2ccc3c(c2)[nH]c(=O)c2c(N)n(-c4cccc(O)c4)nc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.43
SRC P12931 2/20 0.38
FGFR1 P11362 2/20 0.38
KDR P35968 2/20 0.37
PRKD3 O94806 1/20 0.37
PIM1 P11309 1/20 0.37
FLT4 P35916 1/20 0.37
CLK2 P49760 1/20 0.37
GSK3A P49840 1/20 0.37
DYRK1A Q13627 1/20 0.37
PIM3 Q86V86 1/20 0.37
AURKB Q96GD4 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
STK17A Q9UEE5 1/20 0.37
DRD2 P14416 1/20 0.36
PDGFRB P09619 1/20 0.35
TDP2 O95551 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872630 0.96 HTR7 (0.42) HTR7FGFR1KDRPDGFRBTDP2
SCHEMBL2860907 0.92 PIK3CD (0.44) HTR7PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2868580 0.91 KHK (0.42) HTR7SRCFGFR1KDRDRD2
SCHEMBL2861162 0.91 HTR7 (0.40) HTR7DRD2TDP2PIK3CDPIK3CA
SCHEMBL2856171 0.91 FGFR1 (0.38) HTR7SRCFGFR1DRD2SMN1; SMN2
SCHEMBL2862306 0.87 KHK (0.45) HTR7SRCFGFR1KDRPDGFRB
SCHEMBL2868547 0.87 XDH (0.46) FGFR1DRD2
SCHEMBL14375389 0.84 TSHR (0.38) SRCFGFR1PRKD3PIM1GSK3A
SCHEMBL14375315 0.82 PARP1 (0.38) SRCTDP2KDM4EALDH1A1GLA
SCHEMBL2864188 0.79 PARP1 (0.49) KHKALDH1A1GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 HTR7 713/4885SRC 122/4885FGFR1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.